<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Torii Labs LLC

    Torii Labs LLC

    The company creates herbal tonics to balance and build bodies and minds. Torii Lab...

    The company creates herbal tonics to balance an...

    Fundraising Status:    EC
    Filing Type:    CF
    bluebird bio, Inc.

    bluebird bio, Inc.

    bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., h...

    bluebird bio is pioneering gene therapy with pu...

    Filing Type:    PU
    PlantPharm BioMed, Ltd.

    PlantPharm BioMed, Ltd.

    We are a global frontrunner in making oral vaccines a reality. We’ve created a p...

    We are a global frontrunner in making oral vacc...

    Amount Raised:    $0.00
    Fundraising Status:    EC
    Filing Type:    CF
    Gritstone Oncology, Inc.

    Gritstone Oncology, Inc.

    Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight mu...

    Gritstone Oncology is developing tumor-specific...

    Filing Type:    PU
    Chembio Diagnostics, Inc.

    Chembio Diagnostics, Inc.

    Chembio is a leading point-of-care diagnostics company focused on detecting and di...

    Chembio is a leading point-of-care diagnostics ...

    Filing Type:    PU
    Pulse Biosciences, Inc

    Pulse Biosciences, Inc

    Pulse Biosciences is a bioelectric medicine company pursuing commercial introducti...

    Pulse Biosciences is a bioelectric medicine com...

    Filing Type:    PU
    Surface Oncology, Inc.

    Surface Oncology, Inc.

    Surface Oncology is an immuno-oncology company on a mission to break through and d...

    Surface Oncology is an immuno-oncology company ...

    Filing Type:    PU
    Vaccinex, Inc.

    Vaccinex, Inc.

    Vaccinex is a clinical-stage biotechnology company engaged in the discovery and de...

    Vaccinex is a clinical-stage biotechnology comp...

    Filing Type:    PU
    IMV Inc.

    IMV Inc.

    IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunot...

    IMV Inc. is a clinical stage biopharmaceutical ...

    Filing Type:    PU
    Genocea Biosciences, Inc.

    Genocea Biosciences, Inc.

    Genocea is a biopharmaceutical company developing personalized cancer immunotherap...

    Genocea is a biopharmaceutical company developi...

    Filing Type:    PU
    Aravive, Inc.

    Aravive, Inc.

    Aravive is developing treatments designed to halt progression of life-threatening ...

    Aravive is developing treatments designed to ha...

    Filing Type:    PU
    Precipio, Inc.

    Precipio, Inc.

    Precipio has built a platform designed to eradicate the problem of misdiagnosis by...

    Precipio has built a platform designed to eradi...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.